APA

Tarhini A. A., Lee S. J., Hodi F. S., Rao U. N. M., Cohen G. I., Hamid O., Hutchins L. F., Sosman J. A., Kluger H. M., Eroglu Z., Koon H. B., Lawrence D. P., Kendra K. L., Minor D. R., Lee C. B., Albertini M. R., Flaherty L. E., Petrella T. M., Streicher H., Sondak V. K. & Kirkwood J. M. (20200828). Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chicago

Tarhini Ahmad A, Lee Sandra J, Hodi F Stephen, Rao Uma N M, Cohen Gary I, Hamid Omid, Hutchins Laura F, Sosman Jeffrey A, Kluger Harriett M, Eroglu Zeynep, Koon Henry B, Lawrence Donald P, Kendra Kari L, Minor David R, Lee Carrie B, Albertini Mark R, Flaherty Lawrence E, Petrella Teresa M, Streicher Howard, Sondak Vernon K and Kirkwood John M. 20200828. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Harvard

Tarhini A. A., Lee S. J., Hodi F. S., Rao U. N. M., Cohen G. I., Hamid O., Hutchins L. F., Sosman J. A., Kluger H. M., Eroglu Z., Koon H. B., Lawrence D. P., Kendra K. L., Minor D. R., Lee C. B., Albertini M. R., Flaherty L. E., Petrella T. M., Streicher H., Sondak V. K. and Kirkwood J. M. (20200828). Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLA

Tarhini Ahmad A, Lee Sandra J, Hodi F Stephen, Rao Uma N M, Cohen Gary I, Hamid Omid, Hutchins Laura F, Sosman Jeffrey A, Kluger Harriett M, Eroglu Zeynep, Koon Henry B, Lawrence Donald P, Kendra Kari L, Minor David R, Lee Carrie B, Albertini Mark R, Flaherty Lawrence E, Petrella Teresa M, Streicher Howard, Sondak Vernon K and Kirkwood John M. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20200828.